Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Haematology Association

- PMLiVE

NICE issues fresh rejection for Celgene’s cancer drug Imnovid

Drugpricing watchdog says the treatment is too costly for NHS use

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

EU flag

EMA defends Humira redaction policy from transparency criticism

Regulator says spirit of trial transparency intact after its handling of AbbVie reports

- PMLiVE

FDA approves AbbVie’s Duopa in advanced Parkinson’s

Drug is administered into the stomach via a tube

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

- PMLiVE

NICE backs three ulcerative colitis treatments

Remicade, Simponi and Humira recommended for NHS reimbursement

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links